Metraipolis › archive › dc_94fa3725376d

Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan — Europe PMC PMID:41769311

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41769311
DOI
10.1080/20523211.2026.2633832
License (as archived)
solo-consultazione
Archived
2026-10-08T14:29:28.487Z
SHA-256 of the archived text
d14b0d2594d635f9069d8a83940d0cdf534164cf78a25548bf65647c2101ed01
Stable URL of this page
https://metraipolis.com/documento/dc_94fa3725376d

How to cite

Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan — Europe PMC PMID:41769311 — Europe PMC (en), https://europepmc.org/article/MED/41769311 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_94fa3725376d (Metraipolis archive dc_94fa3725376d, sha256 d14b0d2594d635f9069d8a83940d0cdf534164cf78a25548bf65647c2101ed01)
BibTeX
@misc{dc94fa3725376d,
  title = {Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan — Europe PMC PMID:41769311},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41769311},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_94fa3725376d; sha256 d14b0d2594d635f9069d8a83940d0cdf534164cf78a25548bf65647c2101ed01},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41769311. Agents can read the archived copy with the MCP tool read_document.